Tags : Vumerity

Biogen’s Vumerity (diroximel fumarate) Receives the EC’s Approval for the

Tuba Khan November 17, 2021

Shots: The approval is based on the data from PK bridging studies and P-III EVOLVE-MS-2 study to evaluate the GI tolerability of Vumerity vs Tecfidera in patients with relapsing-remitting MS […]readmore

Regulatory

Biogen and Alkermes’ Vumerity (diroximel fumarate) Receive FDA’s Approval for

Vartika Singh October 30, 2019

Shots: The FDA’s approval is based on NDA submitted under the 505(b)(2) filing pathway and contain data from P-III EVOLVE-MS-1 study assessing Vumerity in patients with relapsing-remitting MS In Nov’2017, […]readmore

Tags : Vumerity

Biogen’s Vumerity (diroximel fumarate) Receives the EC’s Approval for the

Biogen and Alkermes’ Vumerity (diroximel fumarate) Receive FDA’s Approval for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Vumerity

Biogen’s Vumerity (diroximel fumarate) Receives the EC’s Approval for the

Biogen and Alkermes’ Vumerity (diroximel fumarate) Receive FDA’s Approval for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company